Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government ... and deliver innovative therapeutics to ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

As a result, life sciences companies are preparing for ... Dividend Yield as of December 28: 3.33% Gilead Sciences, Inc. (NASDAQ:GILD) is a global biopharmaceutical company that develops and ...

Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $92.96 which represents a slight increase of $1.12 or 1.22% from the prior close of $91.84. The stock opened at $92.06 and ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...